Uniseed is a $60 million venture fund operating at the Universities of Melbourne, Queensland and New South Wales, with investment capital provided by the three universities and AustralianSuper – a leading industry superannuation fund. Uniseed’s mandate is to facilitate the commercialisation of university-generated intellectual property by targeted investment in highly promising technologies.

Uniseed’s investments cover a range of technology sectors. To date, the fund has exited two investments through trade sales; an IT security technology (Vintela) and a semi-conductor technology (Fultec). Its biotechnology portfolio is also maturing, with QRxPharma submitting an NDA for its dual opioid therapy, and three other companies at Phase 2 with novel therapies for neuropathic pain (Spinifex), diabetes (Verva) or human head lice (Hatchtech).

Hatchtech appoints new CEO and completes financing round
(26/04/2012)

QRxPharma signs license and option agreement with Actavis
(19/03/2012)

Hatchtech Extends Patent Protection for DeOvo Head Lice Treatment
(15/02/2012)

Verva Pharmaceutical’s license partner Isis Pharmaceuticals, Inc announced the initiation of a Phase 1 study of ISIS-FGFR4Rx, and antisense drug designed to treat obesity
(20/12/2011)

Smart Sparrow targets next generation learning after securing first round of funding
(21/10/2011)

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
(12/09/2011)

Hatchtech completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment DeOvo
(31/08/2011)

QRxPharma Completes NDS Submission for MoxDuo IR
(25/08/2011)

Spinifex Closes AU$18.25M Expanded Series B Round
(23/08/2011)

QRxPharma Announces A$35 Million Capital Raising to progress MoxDuo Formulations and Support Commercialisation of MoxDuo IRs
(22/07/2011)

QRxPharma Announces NDA Filing for MoxDuo IR
(18/07/2011)

$1.1m Sounds Good for Childhood Hearing Problems
(12/07/2011)

QRxPharma Completes Comparative Safety Study
(14/06/2011)

Verva Announces AUD 2M Financing and Results of Annual General Meeting
(13/05/2011)

TenasiTech pioneers nanotechnology for polyurethane industrial seals
(06/05/2011)

QRxPharama MoxDu IR Study
(06/05/2011)

Hatchtech commences 2b Clinical Trial of New-Generation Head Lice Treatment DeOvo
(06/05/2011)

Verva Announces Isis Pharmaceuticals, Inc. Adds FGFR Drug to Development Pipeline
(01/02/2011)

Changes to the Board at Uniseed
(31/12/2010)

QRxPharma Completes A$19.8 Million Capital Raising
(19/11/2010)

Hatchtech raises $6.3 For DeOvo head lice phase2b clinical trial
(26/10/2010)

QRxPharma Limited Announces A$14 Million Placement together with a Share Purchase Plan
(01/10/2010)

BT Imaging Closes Funding Round
(Marketwire - 23/08/10)

Frost & Sullivan recognises QRxPharma’s MoxDuo® IR for innovation in pain therapy
(18/08/2010)

QRxPharma receives positive feedback from scientific advice meetings in Europe on MOXDUO®IR development and registration
(26/07/2010)

Berthold Leibinger
Laserpreis 2010
(08/07/2010)

Uniseed’s Investment Manager Richard Marshall talks about Pepfactant’s win in the Enterprize Competition

QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo^(R) IR in Patients with Post-Surgical Pain
(ASX Release, 14 April 2010)

Hatchtech Positive DeOvo Head Lice Phase II Clinical Trial Result(Media Release, 25 March 2010)